Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin‐resistant ovarian cancer (A2780) cells
- 11 September 2019
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 95 (2) , 215-223
Abstract
Ovarian cancer is considered as one of the most lethal gynecological cancers, and cisplatin‐based therapy has an important role as the first‐line option for chemotherapy. Resistance to chemotherapy is the main obstacle against successful cancer chemotherapy with cisplatin. Therefore, identifying potent compositions and molecules with fewer side‐effects is a big challenge to overcome cisplatin resistance. In this study, we investigated the possible mechanism and potency of sanguinarine, a plant‐derived alkaloid, in human cisplatin‐resistant ovarian cancer (A2780/R) cells. The effect of sanguinarine on cytotoxicity of cisplatin was determined by MTT assay. Apoptosis‐inducing effect of sanguinarine alone and in combination with cisplatin was evaluated by annexin V/PI assay and DAPI staining. Intracellular glutathione (GSH) content was quantitated using GSH assay kit after treatment with sanguinarine. Results indicated that sanguinarine enhances the sensitivity of A2780/R cells to cisplatin. Apoptosis‐inducing effect of cisplatin was also enhanced when combined with sanguinarine. Furthermore, sanguinarine reduced intracellular GSH content in a dose‐dependent but not time‐dependent manner. These findings suggest that sanguinarine could reverse cisplatin resistance in A2780/R cells through GSH reduction. Therefore, sanguinarine can be used as one of the potent adjuvants for ovarian cancer chemotherapy.Keywords
This publication has 26 references indexed in Scilit:
- Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothioneinJournal of Inorganic Biochemistry, 2019
- Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicinGene, 2018
- Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibitionBiochemical Pharmacology, 2014
- Clinical trials and future potential of targeted therapy for ovarian cancerInternational Journal of Clinical Oncology, 2012
- Platinum resistance in breast and ovarian cancer cell linesJournal of Experimental & Clinical Cancer Research, 2011
- Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategiesEuropean Journal of Pharmacology, 2011
- Sanguinarine induces apoptosis in A549 human lung cancer cells primarily via cellular glutathione depletionToxicology in Vitro, 2009
- Hammerhead ribozyme against γ-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteinsCancer Gene Therapy, 2001
- Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agentsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984